# US 2009/0253131 A1 · Hybrid fusion reporter and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0253131 A1
- Document ID: US20090253131A1
- Status: Published application
- Kind: A1
- Application number: 12/265,558
- Filed: 2008-11-05
- Published: 2009-10-08
- Earliest claimed: 2007-11-05
- Assignees: Promega Corporation
- Inventors: Susan Wigdal; Keith V. Wood
- Web page: https://patentgrep.com/patent/US20090253131A1

## CPC

- C12Q 1/66: involving luciferase
- C12Q 1/6897: involving reporter genes operably linked to promoters
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides vectors encoding hybrid fusion proteins and vector sets encoding different hybrid fusion proteins useful, for instance, in protein complementation assays.

## Claims

### Claim 1

A plurality of expression vectors comprising:
a first expression vector comprising a first polynucleotide comprising a promoter operably linked to an open reading frame for a first fusion protein comprising i) a fragment of a reporter protein having at least 50 contiguous amino acid residues of, but having at least 50 fewer amino acid residues than, a corresponding full length reporter protein and ii) a first heterologous amino acid sequence; and
a second expression vector comprising a second polynucleotide comprising a promoter operably linked to an open reading frame for a second fusion protein comprising iii) a fragment of a functionally distinct protein relative to the reporter protein and having at least 50 contiguous amino acid residues of, but having at least 50 fewer amino acid residues than, a corresponding full length functionally distinct protein and iv) a second heterologous amino acid sequence, wherein the reporter activity of the reporter protein fragment is increased in the presence of the functionally distinct protein fragment, and is dependent on the interaction of the first and second heterologous amino acid sequences.

### Claim 2 (depends on 1)

The plurality of vectors of claim 1 wherein the reporter protein is a mutant haloalkane dehalogenase that stably binds a substrate of a corresponding nonmutant haloalkane dehalogenase, wherein the mutant haloalkane dehalogenase comprises at least one amino acid substitution at an amino acid residue corresponding to residue 106 or 272 of a Rhodococcus haloalkane dehalogenase.

### Claim 3 (depends on 2)

The plurality of vectors of claim 2 wherein the functionally distinct protein is an anthozoan luciferase or a monooxygenase.

### Claim 4 (depends on 2)

The plurality of vectors of claim 2 wherein the fragment of the mutant haloalkane dehalogenase comprises at least 50 and up to 250 contiguous amino acids from the C-terminal portion of a corresponding full length mutant haloalkane dehalogenase.

### Claim 5 (depends on 2)

The plurality of vectors of claim 2 wherein the N-terminus of the mutant haloalkane dehalogenase fragment corresponds to a residue in a region corresponding to residues 73 to 103 in a Rhodococcus dehalogenase.

### Claim 6 (depends on 1)

The plurality of vectors of claim 1 wherein the reporter protein is a bioluminescent enzyme or a hydrolase.

### Claim 7 (depends on 1)

The plurality of vectors of claim 1 wherein the reporter protein is a beetle luciferase and the functionally distinct protein is not bioluminescent.

### Claim 8 (depends on 7)

The plurality of vectors of claim 7 wherein the functionally distinct protein is an acyl-CoA ligase, an acyl-thiol ligase, or a fatty acyl-CoA synthetase.

### Claim 9 (depends on 1)

The plurality of vectors of claim 1 wherein the reporter protein is an Oplophorus luciferase and the functionally distinct protein is not bioluminescent.

### Claim 10

An assay for the detection of molecular interactions, or agents or conditions that may alter molecular interactions, comprising fragments of functionally distinct proteins separately fused to molecular domains, wherein the interaction of the molecular domains is detected by reconstitution of the activity of at least one of the distinct proteins.

### Claim 11 (depends on 10)

The assay of claim 10 wherein the functionally distinct proteins are an anthozoan luciferase and a mutant haloalkane dehalogenase or, a beetle luciferase and an acyl-CoA ligase, an acyl-thiol ligase, or a fatty acyl-CoA-synthetase or, an Oplophorus luciferase and a lipophilic transport protein, a retinol binding protein, a fatty acid binding protein, or a nonbioluminescent protein in the FABP-like family of proteins.

### Claim 12

A method of testing molecular interactions comprising:
a) providing a first fusion protein comprising a fragment of a first protein and a first heterologous amino acid sequence;
b) providing a second fusion protein comprising a fragment of a functionally distinct protein relative to the first protein and a second heterologous amino acid sequence selected to interact or suspected of interacting with the first heterologous amino acid sequence;
c) allowing the first and second heterologous amino acid sequences to contact each other; and
d) testing for activity of the first protein or the second protein resulting from the interaction of the first and second heterologous amino acid sequences.

### Claim 13 (depends on 12)

The method of claim 12 wherein the first protein is a mutant haloalkane dehalogenase that stably binds a substrate of a corresponding nonmutant dehalogenase or is a bioluminescent enzyme.

### Claim 14

A composition comprising a first polynucleotide comprising an open reading frame for a first fusion protein comprising a first fragment having at least 50 and up to 250 contiguous amino acid residues from the C-terminal portion of a corresponding full length dehalogenase and a first heterologous amino acid sequence which directly or indirectly interacts with a second heterologous amino acid sequence, wherein the dehalogenase fragment in the presence of a fragment of a functionally distinct protein relative to the dehalogenase comprising at least 50 and up to 150 contiguous amino acid residues from the N-terminal portion of a corresponding full length functionally distinct protein, is capable of stably binding a dehalogenase substrate for a corresponding full length, wild type dehalogenase, wherein the N-terminus of the dehalogenase fragment is at a residue or in a region in a full length, wild type dehalogenase sequence which is tolerant to modification, wherein the dehalogenase fragment corresponds in sequence to a fragment of a full length mutant dehalogenase comprising at least one amino acid substitution at an amino acid residue corresponding to amino acid residue 106 or 272 of a Rhodococcus rhodochrous dehalogenase, which substitution allows the full length mutant dehalogenase to form a bond with a dehalogenase substrate that is more stable than the bond formed between the corresponding full length, wild type dehalogenase and the dehalogenase substrate.

### Claim 15 (depends on 14)

The composition of claim 14 further comprising a second polynucleotide comprising an open reading frame for a second fusion protein comprising the fragment of the functionally distinct protein and the second heterologous amino acid sequence, wherein the interaction between the first and second heterologous amino acid sequences is capable of detection and results in an increase in the binding of a dehalogenase substrate by the dehalogenase fragment, and wherein the C-termini of the functionally distinct protein fragment is at a residue or in a region in the full length, functionally distinct protein which is tolerant to modification.

### Claim 16

A composition comprising a first fusion protein comprising a first fragment having at least 50 and up to 250 contiguous amino acid residues from the C-terminal portion of a corresponding full length dehalogenase and a first heterologous amino acid sequence which directly or indirectly interacts with a second heterologous amino acid sequence, wherein the dehalogenase fragment in the presence of a fragment of a functionally distinct protein relative to the dehalogenase comprising at least 50 and up to 150 contiguous amino acid residues from the N-terminal portion of a corresponding full length functionally distinct protein, is capable of stably binding a dehalogenase substrate for a corresponding full length, wild type dehalogenase, wherein the N-terminus of the dehalogenase fragment is at a residue or in a region in a full length wild type dehalogenase sequence which is tolerant to modification, wherein the dehalogenase fragment corresponds in sequence to a fragment of a full length mutant dehalogenase comprising at least one amino acid substitution at an amino acid residue corresponding to amino acid residue 106 or 272 of a Rhodococcus rhodochrous dehalogenase, which substitution allows the full length mutant dehalogenase to form a bond with a dehalogenase substrate that is more stable than the bond formed between the corresponding full length, wild type dehalogenase and the dehalogenase substrate.

### Claim 17 (depends on 16)

The composition of claim 16 further comprising a second fusion protein comprising the fragment of the functionally distinct protein and the second heterologous amino acid sequence, wherein the interaction between the first and second heterologous amino acid sequences is capable of detection, wherein the interaction between the first and second heterologous amino acid sequences is capable of detection and results in an increase in the binding of a dehalogenase substrate by the dehalogenase fragment, and wherein the C-terminus of the functionally distinct protein fragment is at a residue or in a region in the full length, functionally distinct protein which is tolerant to modification.

### Claim 18 (depends on 15, 17)

The composition of claim 15 or 17 wherein the region tolerant to modification in the functionally distinct protein corresponds to residue 64 to 74, residue 86 to 116, or residue 146 to 156 of a Renilla luciferase.

### Claim 19 (depends on 14, 16)

The composition of claim 14 or 16 wherein the region tolerant to modification in the dehalogenase corresponds to residues 73 to 83, residues 93 to 103, or residues 204 to 214 of a Rhodococcus dehalogenase.

### Claim 20 (depends on 14)

A vector comprising the first polynucleotide in the composition of claim 14.

### Claim 21 (depends on 15)

A vector comprising the second polynucleotide in the composition of claim 15.

### Claim 22 (depends on 14, 15, 16)

A host cell comprising the composition of claim 14 to 16.

### Claim 23

A plurality of expression vectors comprising a first expression vector comprising a first promoter operably linked to an open reading frame for a first fusion protein comprising a first fragment having at least 50 and up to 250 contiguous amino acid residues from the C-terminal portion of a corresponding full length dehalogenase and a first heterologous amino acid sequence which directly or indirectly interacts with a second heterologous amino acid sequence, wherein the N-terminus of the dehalogenase fragment is at a residue or in a region in a full length, wild type dehalogenase sequence which is tolerant to modification, wherein the dehalogenase fragment corresponds in sequence to a fragment of a full length mutant dehalogenase comprising at least one amino acid substitution at an amino acid residue corresponding to amino acid residue 106 or 272 of a Rhodococcus rhodochrous dehalogenase, which substitution allows the full length mutant dehalogenase to form a bond with a dehalogenase substrate that is more stable than the bond formed between the corresponding full length, wild type dehalogenase and the dehalogenase substrate; and
a second expression vector comprising a second promoter operably linked to an open reading frame for a second fusion protein comprising a fragment of the functionally distinct protein relative to the dehalogenase comprising at least 50 and up to 150 contiguous amino acid residues from the N-terminal portion of a corresponding full length functionally distinct protein and the second heterologous amino acid sequence, and wherein the C-terminus of the functionally distinct protein fragment is at a residue or in a region in the full length functionally distinct protein which is tolerant to modification,
and wherein the interaction between the first and second heterologous amino acid sequences is capable of detection and results in an increase in the binding of a dehalogenase substrate by the dehalogenase fragment.

### Claim 24 (depends on 23)

The plurality vectors of claim 23 wherein the mutant dehalogenase comprises at least two amino acid substitutions relative to a corresponding full length, wild type dehalogenase, and wherein a second substitution is at an amino acid residue in the full length, wild type dehalogenase that is within the active site cavity.

### Claim 25 (depends on 23)

A method to detect an interaction between two proteins in a sample, comprising:
a) providing a sample having a cell expressing fusion proteins encoded by the plurality of vectors of claim 23, a lysate of the cell, or an in vitro transcription/translation reaction expressing fusion proteins encoded by the plurality of vectors of claim 23, and a dehalogenase substrate with at least one functional group under conditions effective to allow for association of the first and second heterologous amino acid sequences; and
b) detecting in the sample the presence, amount or location of the at least one functional group bound to the dehalogenase fragment, thereby detecting whether the two heterologous sequences interact.

### Claim 26 (depends on 23)

A method to detect an agent that alters the interaction of two proteins, comprising:
a) providing a sample having a cell expressing fusion proteins encoded by the plurality of vectors of claim 23, a lysate thereof, or an in vitro transcription/translation reaction expressing fusion proteins encoded by the plurality of vectors of claim 23, a dehalogenase substrate with at least one functional group, and an agent under conditions effective to allow for association of the first and second heterologous sequences, wherein the agent is suspected of altering the interaction of the first and second heterologous amino acid sequences; and
b) detecting in the sample the presence or amount of the at least one functional group bound to the dehalogenase fragment relative to a sample without the agent.

### Claim 27 (depends on 23)

A method to detect a condition that alters the interaction of two proteins, comprising:
a) providing a sample subjected to a condition, wherein the sample comprises a cell expressing fusion proteins encoded by the plurality of vectors of claim 23, a lysate thereof, or an in vitro transcription/translation reaction expressing fusion proteins encoded by the plurality of vectors of claim 23;
b) adding to the sample a dehalogenase substrate with at least one functional group; and
c) detecting in the sample the presence or amount of the at least one functional group bound to the dehalogenase fragment relative to a sample not subjected to the condition.

### Claim 28 (depends on 25)

The method of claim 25 further comprising contacting the sample with an agent or subjecting the sample to conditions which alter the conformation of the first and/or second heterologous amino acid sequence.

### Claim 29

A composition comprising a first polynucleotide comprising an open reading frame for a first fusion protein comprising i) a first fragment of an anthozoan luciferase comprising at least 50 and up to 250 contiguous amino acid residues from the C-terminal portion of a corresponding full length anthozoan luciferase, a first fragment of a beetle luciferase comprising at least 50 and up to 450 contiguous amino acid residues from the C-terminal portion of a corresponding full length beetle luciferase or a first fragment of a decapod luciferase comprising at least 40 and up to 150 contiguous amino acid residues of the C-terminus of a corresponding full length decapod luciferase, wherein the N-terminus of the anthozoan luciferase, beetle luciferase or decapod luciferase fragment is at a residue or in a region in a full length, wild type anthozoan luciferase, beetle luciferase or decapod luciferase sequence which is tolerant to modification, and ii) a first heterologous amino acid sequence which directly or indirectly interacts with a second heterologous amino acid sequence; and
a second polynucleotide comprising an open reading frame for a second fusion protein comprising a fragment of a functionally distinct protein relative to the luciferase comprising at least 40 and up to 250 contiguous amino acid residues from the N-terminal portion of a corresponding full length functionally distinct protein and the second heterologous amino acid sequence, wherein the C-terminus of the functionally distinct protein is at a residue or in a region in the full length, functionally distinct protein which is tolerant to modification,
wherein the interaction between the first and second heterologous amino acid sequences is capable of detection and results in an increase in the luciferase activity.

### Claim 30 (depends on 29)

The composition of claim 29 wherein the region tolerant to modification in the beetle luciferase is in a region corresponding to residue 102 to 126, residue 139 to 165, residue 203 to 193, residue 220 to 247, residue 262 to 273, residue 303 to 313, residue 353 to 408, or residue 485 to 495 of a firefly luciferase.

### Claim 31 (depends on 30)

The composition of claim 30 wherein the first fragment is a firefly luciferase fragment.

### Claim 32 (depends on 31)

The composition of claim 31 wherein the functionally distinct protein is not a bioluminescent protein.

### Claim 33 (depends on 32)

The composition of claim 32 wherein the functionally distinct protein is a fatty acyl-CoA synthetase.

### Claim 34 (depends on 29)

The composition of claim 29 wherein the region tolerant to modification in the anthozoan luciferase corresponds to residue 64 to 74, residue 86 to 116, or residue 146 to 156 of a Renilla luciferase or wherein the region tolerant to modification in the decapod luciferase corresponds to residue 45 to 55 or residue 79 to 89 of an Oplophorus luciferase.

### Claim 35 (depends on 34)

The composition of claim 34 wherein the first fragment is a Renilla luciferase fragment or an Oplophorus luciferase fragment.

### Claim 36 (depends on 35)

The composition of claim 35 wherein the functionally distinct protein is not a bioluminescent protein.

### Claim 37 (depends on 36)

The composition of claim 36 wherein the functionally distinct protein is a dehalogenase.

### Claim 38 (depends on 36)

The composition of claim 36 wherein the functionally distinct protein is a lipophilic transport protein, a retinol binding protein or a fatty acid binding protein.
